Brief: Reg-Basilea Reports H1 Diluted Loss Per Share of CHF 1.03

Basilea Pharmaceutica AG, Allschwil

16/08/2022 06:20

Aug 16 (Reuters) - Basilea Pharmaceutica AG  BSLN.S :
    * REG-BASILEA REPORTS STRONG FINANCIAL HALF-YEAR RESULTS AND
PROGRESS IN THE IMPLEMENTATION OF NEW ANTI-INFECTIVES STRATEGY
    * TOTAL REVENUE IN FIRST HALF-YEAR 2022 INCREASED 8.2% TO
CHF 58.6
MILLION
    * FULL-YEAR 2022 GUIDANCE CONFIRMED AS WELL AS EXPECTED
SUSTAINABLE PROFITABILITY FROM 2023
    * H1 DILUTED LOSS PER SHARE CHF 1.03
    * SEES FY2022 TOTAL REVENUE CHF 106 MILLION TO CHF 112
MILLION
    * BASILEA PHARMACEUTICA - IN SECOND HALF OF 2022, CO WILL
FOCUS ON
NDA SUBMISSION FOR CEFTOBIPROLE IN U.S.; COMPLETING TRANSACTIONS
FOR ONCOLOGY ASSETS

Source text for Eikon:  ID:nGNE7vCh8H 
Further company coverage:  BSLN.S 

 ((Reuters.Briefs@thomsonreuters.com;))